Partners Kelly Gibson and Carolyn Welshhans authored a Law360 Expert Analysis article discussing the shifting enforcement priorities of the US Securities and Exchange Commission (SEC) under the current administration, highlighting that companies in healthcare, biotech, and pharmaceuticals face increased scrutiny related to regulatory disclosures, insider trading, and cybersecurity.
The authors outline practical steps for companies to mitigate risk, including updating disclosures, strengthening insider trading controls, enhancing cybersecurity protocols, and ensuring accurate public communications.